Progress for patients is possible this
CIDP Awareness Month
This May, join us in raising awareness of chronic inflammatory demyelinating polyneuropathy (CIDP) to make meaningful progress for patients living with this rare neurological disease. Greater awareness can lead to better disease evaluation and more informed treatment selection. Together we can help uncover the full impact of CIDP and work toward greater functional progress.
Tips for deeper evaluation of CIDP
1. Uncover the hidden impact of CIDP
- CIDP is a rare, often progressive immune-mediated neuromuscular disorder1-3
- Symptoms, which include motor and sensory impairment, can be debilitating and affect quality of life1,4,5
- Even with traditional treatments, many patients experience ongoing challenges with their disease burden4,6,7
Traditional CIDP treatments include IVIG, SCIG, corticosteroids, and PLEX.1
2. Measure what matters with standardized evaluation tools
- Treatment for CIDP has evolved, but satisfaction with traditional therapies remains uneven8*
- Incorporating the use of standardized outcome measures into routine practice may help identify where patient and HCP perceptions may diverge9,10
- Evaluation tools such as grip strength, INCAT, and I-RODS can help measure disability and assess treatment response1
3. Discover emerging science in CIDP pathophysiology
- While the exact pathophysiology of CIDP is complex and not completely understood, IgG autoantibodies may be the key to understanding the mechanisms of CIDP11-13
- Autoantibodies, including IgG autoantibodies, may lead to demyelination which can contribute to axonal damage11,13-15
- FcRn recycles IgG antibodies, including IgG autoantibodies, and understanding this process can open new opportunities for intervention15-19
*From a real-world, cross-sectional survey including patients with CIDP (n=76) and their neurologists in the US, conducted between September 2022-April 2023. Treatments included immunoglobulins, corticosteroids, nonsteroidal immunosuppressants, biologics, neuropathic pain therapies, or plasmapheresis.20,21
CIDP=chronic inflammatory demyelinating polyneuropathy; FcRn=neonatal Fc receptor; HCP=healthcare professional; IgG=immunoglobulin G; INCAT=Inflammatory Neuropathy Cause and Treatment; I-RODS=Inflammatory Rasch‐built Overall Disability Scale; IVIG=intravenous immunoglobulin; PLEX=plasma exchange; SCIG=subcutaneous immunoglobulin.
Additional resources to support you and your patients during CIDP Awareness Month
Get a grasp on device-measured grip strength.
See real patients with CIDP share their stories.
CIDP=chronic inflammatory demyelinating polyneuropathy.
Want to know more about CIDP? Visit the GBS|CIDP Foundation website to find out more
about this rare disease.
CIDP=chronic inflammatory demyelinating polyneuropathy; GBS=Guillain-Barré syndrome.
References: 1. Van den Bergh PYK et al. Eur J Neurol. 2021;28(11):3556-3583. doi:10.1111/ene.14959 2. Broers MC et al. Neuroepidemiology. 2019;52(3-4):161-172. doi:10.1159/000494291 3. Brun S et al. Immuno. 2022;2:118-131. doi:10.3390/immuno2010009 4. Querol L et al. J Neurol. 2021;268(10):3706-3716. doi:10.1007/s00415-020-09998-8 5. Ryltoft AK et al. Acta Neurol Scand. 2020;00:1-4. doi:10.1111/ane.13322 6. Bunschoten C et al. J Peripher Nerv Syst. 2019;24(3):253-259. doi:10.1111/jns.12344 7. Bunschoten C et al. Lancet Neurol. 2019;18(8):784-794. doi:10.1016/S1474-4422(19)30144-9 8. Data on file. REF-05153. argenx US Inc. March 2026. 9. Allen JA et al. US Neurology. 2017;13(1):26-34. doi:10.17925/USN.2017.13.01.26 10. van Doorn IN et al. Ther Clin Risk Manag. 2024;20:111-126. doi:10.2147/TCRM.S360249 11. Mathey EK et al. J Neurol Neurosurg Psychiatry. 2015;86(9):973-985. doi:10.1136/jnnp-2014-309697 12. Querol LA et al. Neurotherapeutics. 2022;19(3):864-873. doi:10.1007/s13311-022-01221-y 13. Dziadkowiak E et al. Int J Mol Sci. 2022;23:2-13. doi:10.3390/ijms23010179 14. Koike H et al. Neurol Ther. 2020;9:213-227. doi:10.1007/s40120-020-00190-8 15. Al-Zuhairy A et al. Clin Neurophysiol. 2021;132(4):1000-1007. doi:10.1016/j.clinph.2020.12.017 16. Ricciardi D et al. Brain Sci. 2022;12(11):1510. doi:10.3390/brainsci12111510 17. Al-Zuhairy A et al. Muscle Nerve. 2022;66(6):715-722. doi:10.1002/mus.27722 18. Ulrichts P et al. J Clin Invest. 2018;128(10):4372-4386. doi:10.1172/JCI97911 19. Wolfe GI et al. J Neurol Sci. 2021;430:118074. doi:10.1016/j.jns.2021.118074 20. Nowacek D et al. Presented at: 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference; March 16-19, 2025; Dallas, TX. 21. Karkare S et al. Presented at: The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting; Oct 29-Nov 1, 2025; San Francisco, CA.
